CTRI/2013/03/003488
Completed
Phase 3
To study the safety and efficacy of use of Mifepristone along with Misoprostol for medical termination of pregnancy in second trimester (12-20weeks)
Dr Pushpa Junghare0 sites100 target enrollmentTBD
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Dr Pushpa Junghare
- Enrollment
- 100
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Women wanting to undergo second trimester medical termination of pregnancy (12\-20weeks)
Exclusion Criteria
- •Known hypersensitivity to Mifepristone or Misoprostol
- •Women with medical renal disease,liver disease
- •Women with heart disease
- •Hb less than 8gm%
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A Randomised Controlled Trial on Efficacy of mifepristone followed by 6-8 hours versus 24 hours vaginal misoprostol in Early Pregnancy Abortions (< 63 days gestations) - TIMES studyMedical termination of pregnancies before nine weeks of pregnancyEUCTR2009-010277-21-GBCalthorpe Clinic
Completed
Not Applicable
Comparing efficacy of vaginal misoprostol administered at 6-8 hours with 24 hours administration after 200 mg of oral mifepristone for early medical abortionsISRCTN97410750Calthorpe Clinic (UK)1,200
Recruiting
Phase 3
Investigating the efficacy and safety of Umifenovir in controlling the symptoms of patients with COVID-19IRCT20080901001165N46Center for Progress and Development of Iran200
Recruiting
Phase 2
To compare Oral Mifepristone with Foley catheter for softening of cervix in women planned for delivery at or after 39 weeks of pregnancyCTRI/2021/07/034943JIPMER INTRAMURA
Completed
Phase 3
mifenovir effectiveness in the treatment of COVID-19IRCT20200322046833N1Center for Progress and Development of Iran100